Research
Search
Close
WU Lingyun
- Chief Physician, Doctoral Supervisor
- Department: Hematology
- Research Area: Internal Medicine (Hematology)
- Research Interests: Pathogenesis of myelodysplastic syndromes
- Contact: lincy2032@163.com
- MD from Shanghai Jiao Tong University School of Medicine, 2013
- PhD from Shanghai Jiao Tong University, School of Medicine, 2013
- MPH from Shanghai Jiao Tong University, School of Medicine, 2006
- Associate Director, Department of Hematology, Shanghai Sixth People's Hospital
- Member of the hematology committee, Society of Shanghai Medical Association; Member of the Hematology Branch of the Chinese Society of Geriatrics
- Jin J, Chen BY, …, Wu L#. ROBO1 deficiency impairs HSPC homeostasis and erythropoiesis via CDC42 and predicts poor prognosis in MDS. Sci Adv. 2023;9(48):eadi7375. doi: 10.1126/sciadv.adi7375.
- Zhu Y, Song D,..., Wu L#. U2AF1 mutation promotes tumorigenicity through facilitating autophagy flux mediated by FOXO3a activation in myelodysplastic syndromes. Cell Death Dis. 2021;12(7):655.doi: 10.1038/s41419-021-03573-3.
- Li X, Xu F,..., Wu L#. Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome. Clin Epigenetics. 2021;13(1):169. doi: 10.1186/s13148-021-01157-8.
- Chen J, Jin J, ..., Wu L#. The bcl6 corepressor mutation regulates the progression and transformation of myelodysplastic syndromes by repressing the autophagy flux. The international journal of biochemistry & cell biology. 2023;165, 106480. doi: 10.1016/j.biocel.2023.106480.
- Wu L, Li X, Xu F, et al. NPM1 Mutation With DNMT3A Wild Type Defines a Subgroup of MDS With Particularly Favourable Outcomes After Decitabine Therapy. Br J Haematol,2020;189(5):982-984. doi:10.1111/bjh.16628.
- Zhu Y, Wu L#. Identification of latent core genes and pathways associated with myelodysplastic syndromes based on integrated bioinformatics analysis. Hematology. 2020;25(1):299-308. doi:10.1080/16078454.2020.1802917
- Xiu C, Li X, Wu L#, Xu F,et al. The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine. J Cancer Res Clin Oncol. 2019;145(12):3089-3097. doi: 10.1007/s00432-019-03031-w
- Qi Y, Li X, ..., Wu L#. Ribosomal protein L23 negatively regulates cellular apoptosis via the RPL23/Miz-1/c-Myc circuit in higher-risk myelodysplastic syndrome. Sci Rep. 2017;7(1):2323.
- Wu L, Shi W, Li X, et al. High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome. J Transl Med. 2016;14(1):66. doi: 10.1186/s12967-016-0817-9.
- Xu F#, Wu LY#, Chang CK, et al. Whole-exome and targeted sequencing identify ROBO1 and ROBO2 mutations as progression-related drivers in myelodysplastic syndromes. Nat Commun. 2015;6:8806. doi: 10.1038/ncomms9806.
